Table 1.
The relationship between miR-204 expression and clinicopathological features in PTC patients from TCGA data set
| Variables | Number of patients | Mean expression of miR-204 (log2[RPKM]) | P-values |
|---|---|---|---|
|
| |||
| Gender | |||
| Male | 136 | 4.28±2.15 | 0.763 |
| Female | 369 | 4.08±2.14 | |
| Age (years) | |||
| ≤45 | 238 | 4.21±2.13 | 0.617 |
| >45 | 267 | 4.06±2.16 | |
| Histologic type | |||
| Follicular variant | 102 | 5.83±2.16 | <0.001*,a |
| Classic variant | 357 | 3.78±1.95 | |
| Tall cell variant | 37 | 2.66±1.03 | |
| Multifocality | |||
| Unifocal | 269 | 4.06±2.14 | 0.932 |
| Multifocal | 228 | 4.21±2.13 | |
| Extrathyroidal extension | |||
| None | 336 | 4.45±2.17 | <0.001* |
| Minimal (T3) + moderate/advanced (T4a) | 151 | 3.30±1.74 | |
| T stage | |||
| T1 + T2 | 311 | 4.42±2.20 | 0.005* |
| T3 + T4 | 192 | 3.66±1.94 | |
| N stage | |||
| N0 | 231 | 4.74±2.26 | <0.001* |
| N1 | 224 | 3.38±1.70 | |
| M stage | |||
| M0 | 281 | 3.98±1.98 | 0.267 |
| M1 | 9 | 4.04±2.52 | |
| AJCC TNM stage | |||
| Stage I + II | 336 | 4.36±2.17 | 0.062 |
| Stage III + IV | 167 | 3.67±2.01 | |
| BRAF mutation | |||
| Without mutation | 265 | 5.15±2.19 | <0.001* |
| BRAF V600E | 240 | 3.00±1.40 | |
| Disease-free status | |||
| Disease free | 444 | 4.16±2.12 | 0.154b |
| Recurred/progressed | 47 | 3.84±2.36 | |
| Overall survival status | |||
| Living | 489 | 4.13±2.14 | 0.355b |
| Deceased | 16 | 4.30±2.03 | |
Notes: Mean expression of miR-204 is represented as the mean value ± SD. Patients with missed data were excluded.
*
P<0.05.
a
P-value by one-way ANOVA.
b
P-value by log-rank test.
Abbreviations: AJCC, American Joint Committee on Cancer; PTC, papillary thyroid carcinoma; RPKM, per kilobase per million; TCGA, the Cancer Genome Atlas.